Salarius: Q3 Earnings Snapshot
Thursday, Nov 14, 2024 7:32 pm ET
2min read Salarius Pharmaceuticals, Inc. (SLRX) recently reported its Q3 2021 financial results, providing insights into the company's progress and strategic initiatives. The report highlights key developments in Salarius' clinical trials, partnerships, and financial performance, offering investors a snapshot of the company's current status and future prospects.
**Clinical Trial Progress and Site Expansion**
Salarius' clinical trial enrollment and site expansion efforts have made significant strides in Q3 2021. The company added five new clinical sites to its sarcoma trial, bringing the total to 13 active sites supporting enrollment. This expansion allows for increased patient access to potential treatments and accelerates the company's clinical programs.
Additionally, Salarius fully enrolled the initial safety lead-in portion of the Ewing sarcoma combination therapy cohort, evaluating seclidemstat in combination with topotecan and cyclophosphamide. Enrollment continues in the cohort evaluating single-agent seclidemstat in myxoid liposarcoma and other FET-rearranged sarcomas. These advancements demonstrate Salarius' commitment to advancing its clinical programs and expanding access to potential treatments for patients in need.
**Strategic Partnerships and Collaborations**
Salarius' partnerships and collaborations have significantly contributed to the advancement of its drug development pipelines. In Q3 2021, the company reported adding five new clinical sites to its sarcoma trial, bringing the total to 13 active sites supporting enrollment. This expansion, coupled with the completion of the initial safety lead-in portion of the Ewing sarcoma combination therapy cohort, demonstrates Salarius' commitment to accelerating its clinical trials.
Furthermore, the company established a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify additional indications and potential biomarkers for seclidemstat. This collaboration, along with data presented by Nationwide Children's Hospital at the 2021 AACR-NCI-EORTC Conference, showcases Salarius' efforts to bolster its seclidemstat clinical and non-clinical research. These partnerships and collaborations have not only expanded Salarius' clinical trial footprint but also strengthened its drug development pipeline, contributing to its overall progress.
**Financial Performance and Outlook**
In Q3 2021, Salarius reported a net loss per common share – basic and diluted – for continuing operations of $0.08 and $0.22, respectively, compared to $0.10 and $0.40 for the same periods last year. The company's total working capital stood at $33.6 million as of September 30, 2021, with a receipt of $2.7 million disbursement from the Cancer Prevention and Research Institute of Texas (CPRIT) announced.
Salarius' cash and cash equivalents of $31.9 million are sufficient to fund the completion of ongoing clinical trials for its lead drug candidate, seclidemstat. The company's financial performance and strategic initiatives position it well to continue advancing its drug development pipelines and delivering value to investors.
In conclusion, Salarius' Q3 2021 earnings snapshot highlights the company's progress in clinical trial enrollment and site expansion, strategic partnerships, and financial performance. These developments underscore Salarius' commitment to advancing its drug development pipelines and delivering value to investors. As the company continues to make strides in its clinical programs and partnerships, investors should monitor Salarius' progress closely to capitalize on potential opportunities in the biopharmaceutical sector.
**Clinical Trial Progress and Site Expansion**
Salarius' clinical trial enrollment and site expansion efforts have made significant strides in Q3 2021. The company added five new clinical sites to its sarcoma trial, bringing the total to 13 active sites supporting enrollment. This expansion allows for increased patient access to potential treatments and accelerates the company's clinical programs.
Additionally, Salarius fully enrolled the initial safety lead-in portion of the Ewing sarcoma combination therapy cohort, evaluating seclidemstat in combination with topotecan and cyclophosphamide. Enrollment continues in the cohort evaluating single-agent seclidemstat in myxoid liposarcoma and other FET-rearranged sarcomas. These advancements demonstrate Salarius' commitment to advancing its clinical programs and expanding access to potential treatments for patients in need.
**Strategic Partnerships and Collaborations**
Salarius' partnerships and collaborations have significantly contributed to the advancement of its drug development pipelines. In Q3 2021, the company reported adding five new clinical sites to its sarcoma trial, bringing the total to 13 active sites supporting enrollment. This expansion, coupled with the completion of the initial safety lead-in portion of the Ewing sarcoma combination therapy cohort, demonstrates Salarius' commitment to accelerating its clinical trials.
Furthermore, the company established a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify additional indications and potential biomarkers for seclidemstat. This collaboration, along with data presented by Nationwide Children's Hospital at the 2021 AACR-NCI-EORTC Conference, showcases Salarius' efforts to bolster its seclidemstat clinical and non-clinical research. These partnerships and collaborations have not only expanded Salarius' clinical trial footprint but also strengthened its drug development pipeline, contributing to its overall progress.
**Financial Performance and Outlook**
In Q3 2021, Salarius reported a net loss per common share – basic and diluted – for continuing operations of $0.08 and $0.22, respectively, compared to $0.10 and $0.40 for the same periods last year. The company's total working capital stood at $33.6 million as of September 30, 2021, with a receipt of $2.7 million disbursement from the Cancer Prevention and Research Institute of Texas (CPRIT) announced.
Salarius' cash and cash equivalents of $31.9 million are sufficient to fund the completion of ongoing clinical trials for its lead drug candidate, seclidemstat. The company's financial performance and strategic initiatives position it well to continue advancing its drug development pipelines and delivering value to investors.
In conclusion, Salarius' Q3 2021 earnings snapshot highlights the company's progress in clinical trial enrollment and site expansion, strategic partnerships, and financial performance. These developments underscore Salarius' commitment to advancing its drug development pipelines and delivering value to investors. As the company continues to make strides in its clinical programs and partnerships, investors should monitor Salarius' progress closely to capitalize on potential opportunities in the biopharmaceutical sector.
Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.